Polymerase Chain Reaction Molecular Diagnostics Market Report 2026

The polymerase chain reaction molecular diagnostics market size has grown strongly in recent years. It will grow from $9.75 billion in 2025 to $10.59 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to expansion of hospital-based molecular diagnostics, increasing prevalence of infectious diseases, availability of standardized pcr diagnostic kits, growth of centralized diagnostic laboratories, regulatory approvals for molecular tests.

The polymerase chain reaction molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing adoption of point-of-care molecular diagnostics, rising investment in personalized medicine, expansion of genomic testing programs, growing demand for decentralized diagnostics, increased integration of digital health platforms. Major trends in the forecast period include increasing use of pcr for infectious disease detection, growing demand for high-sensitivity molecular diagnostics, expansion of pcr-based oncology testing, rising integration of automated diagnostic platforms, enhanced focus on rapid turnaround testing.

The increasing prevalence of infectious diseases is expected to drive the growth of the polymerase chain reaction molecular diagnostics market going forward. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly between individuals. The rising incidence of infectious diseases is partly driven by the emergence of antibiotic resistant pathogens, which are more difficult to treat and control, resulting in longer illness duration, increased healthcare costs, and heightened public health risks. Polymerase chain reaction molecular diagnostics support infectious disease management by enabling rapid and precise detection of pathogens at the genetic level, allowing for early diagnosis and targeted treatment. This contributes to improved healthcare outcomes by supporting timely intervention, limiting disease transmission, and enhancing patient care. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, there were 2,214 newly reported cases of acute hepatitis B in 2023, along with 1,769 hepatitis B related deaths during the same year. Therefore, the rising prevalence of infectious diseases is driving the growth of the polymerase chain reaction molecular diagnostics market.

Major companies operating in the polymerase chain reaction molecular diagnostics market are focusing on the development of advanced technological solutions, such as benchtop instruments, to improve testing efficiency and accessibility. Benchtop instruments are compact, laboratory grade systems designed to fit on workbenches and are used for scientific, medical, or industrial testing and analysis. For instance, in September 2024, QIAGEN N.V., a Germany-based biotechnology company, launched the QIAcuityDx Digital PCR System for clinical oncology testing. The system offers fully automated, walk away processing by integrating partitioning, thermocycling, and imaging into a single platform, enabling absolute quantification of deoxyribonucleic acid and ribonucleic acid with results available in approximately two hours and minimal hands on time. It supports up to five detection channels for multiplex testing, continuous nanoplate loading, and provides both validated clinical and flexible research modes, making it suitable for a wide range of laboratory and clinical requirements.

In May 2024, Bruker Corporation, a US-based manufacturer of advanced analytical instruments, acquired ELITechGroup for $930.9 million. Through this acquisition, Bruker Corporation aims to enhance its molecular diagnostics capabilities and expand its product portfolio in infectious disease diagnostics to better serve hospitals and clinical laboratories worldwide. ELITech Group SAS is an Italy-based in vitro diagnostics company specializing in polymerase chain reaction molecular diagnostic solutions.

Major companies operating in the polymerase chain reaction molecular diagnostics market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Agilent Technologies Inc., Illumina Inc., bioMereieux SA, Sysmex Corporation, Bio Rad Laboratories Inc., QuidelOrtho Corporation, PerkinElmer, Eppendorf AG, Tecan Group, Takara Bio Inc., Biocartis NV, Zymo Research Corporation, QIAGEN N.V., Cepheid Inc., Meridian Bioscience Inc., LGC Biosearch Technologies, Analytik Jena AG, Promega Corporation, BGI Genomics Co. Ltd.

North America was the largest region in the polymerase chain reaction molecular diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymerase chain reaction molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polymerase chain reaction molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the polymerase chain reaction molecular diagnostics market by increasing costs of imported diagnostic instruments, reagents, primers, probes, and analytical software used in clinical testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported molecular diagnostic systems, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are increasing diagnostic test pricing and slowing laboratory expansion. However, they are also encouraging domestic production of diagnostic kits, regional instrument manufacturing, and strengthened local supply chains for molecular diagnostic technologies.

The polymerase chain reaction molecular diagnostics market research report is one of a series of new reports that provides polymerase chain reaction molecular diagnostics market statistics, including polymerase chain reaction molecular diagnostics industry global market size, regional shares, competitors with a polymerase chain reaction molecular diagnostics market share, detailed polymerase chain reaction molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the polymerase chain reaction molecular diagnostics industry. This polymerase chain reaction molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polymerase chain reaction molecular diagnostics is a laboratory technique used to amplify and analyze specific deoxyribonucleic acid or ribonucleic acid sequences within a sample. Its primary function is to detect the presence of particular genetic material, enabling the identification of pathogens, genetic disorders, or mutations. This technique is widely applied in medical diagnostics to detect infectious diseases, genetic abnormalities, and cancer biomarkers with high sensitivity and accuracy.

The main product types in polymerase chain reaction molecular diagnostics include instruments, reagents and consumables, and software. Instruments are devices designed to carry out specific tasks or measurements within scientific and medical settings. The technologies used include real time polymerase chain reaction, digital polymerase chain reaction, and conventional polymerase chain reaction, and they are compatible with sample types such as blood, saliva, tissue, and urine. Polymerase chain reaction molecular diagnostics are utilized in applications including infectious disease testing, oncology testing, and other diagnostic areas, and are used by end users such as hospitals, diagnostic laboratories, and other healthcare facilities.

The polymerase chain reaction molecular diagnostics market consists of revenues earned by entities by providing services such as infectious disease testing, genetic disorder screening, pharmacogenomics testing, deoxyribonucleic acid amplification services, and viral load monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymerase chain reaction molecular diagnostics market also includes sales of thermal cyclers, electrophoresis systems, assay kits, and reverse transcriptase enzymes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.